Drugs.com adds custom 3D animation

Share this article:
Drugs.com adds custom 3D animation
Drugs.com adds custom 3D animation

Drugs.com partnered with Understand.com, a 3D animation and patient education firm, to deliver branded video and education tools for consumers and its advertising partners.

Animation and educational content for a given brand will be developed on a custom basis with drugmakers, and will be placed on the Drugs.com site. The 3D animations will also be made available for use on pharma web properties, according to Rob Griffin, SVP of business development at Understand.com. The joint program, called The Mechanism For Action, is PhRMA compliant and designed "for consumers to take action," according to the Understand.com website.

Griffin said the content is PhRMA compliant in that pharma companies can give the animation and video materials to doctors for use with their patients, and it doesn't qualify as a gift since it's designated for educational purposes. The goal is to educate patients, and that new comprehension "will drive adherence and compliance," said Griffin.

Drugs.com posted a sample of the new content online, which features a six-step 3D video explaining how finasteride — the active ingredient in Merck's Propecia — works to regrow hair. "Ninety percent of the [mechanism of action animation] out there is targeted to doctors," said Griffin. "We want to educate the consumer."

Drugs.com joined the WebMD Health Network at the beginning of 2010, which provides WebMD with exclusive consumer advertising rights on the site, including all display or banner ads. The Drugs.com website is owned and operated by the Drugsite Trust, a privately held trust administered by two pharmacists in New Zealand, according to the website.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders

Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...